A high-level delegation led by the Department of Health — Abu Dhabi, has embarked on a strategic mission to the US from June 14 to 21. The visit reaffirms Abu Dhabi’s global leadership in healthcare innovation and reflects its broader vision for healthcare transformation — driven by innovation, investment, and a deep commitment to global collaboration.
The delegation is visiting key US cities including Boston, Washington, DC, and Philadelphia, in parallel with Abu Dhabi’s participation at BIO International Convention 2025, one of the world’s foremost biotechnology events. The visit spotlights the emirate’s achievements in AI, digital health, genomics, and clinical research and showcases Abu Dhabi’s Health, Endurance, Longevity and Medicine Life Science Cluster, while promoting long-term strategic partnerships with government entities, research institutions, and global innovators.
Dr. Noura Khamis Al-Ghaithi, undersecretary of the Department of Health — Abu Dhabi, said: “This mission reflects our commitment to shaping the future of health through collaboration, innovation, and shared purpose. Our vision is to build a health system that predicts, prevents, acts to restore, and acts to cure, therefore ensuring better outcomes for our communities and beyond. This can only be achieved through meaningful partnerships and a shared ambition to improve lives. We are proud to join our partners in the US to explore new opportunities that advance healthcare, both in the UAE and globally.”
The delegation will conduct over 20 strategic meetings and visits with public and private sector leaders across the US, aimed at knowledge exchange, investment opportunities, and the signing of new agreements that accelerate the adoption of advanced health solutions.
Representing Abu Dhabi’s innovation ecosystem, the delegation includes key stakeholders such as the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, and Etihad Cargo.
